For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Repligen Corp (NASDAQ: RGEN) was $114.8 for the day, down -1.25% from the previous closing price of $116.25. In other words, the price has decreased by -$1.25 from its previous closing price. On the day, 1.19 million shares were traded. RGEN stock price reached its highest trading level at $117.38 during the session, while it also had its lowest trading level at $113.17.
Ratios:
Our analysis of RGEN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 53.87. For the most recent quarter (mrq), Quick Ratio is recorded 5.79 and its Current Ratio is at 6.79. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on June 24, 2025, initiated with a Overweight rating and assigned the stock a target price of $150.
On April 29, 2025, Wolfe Research Upgraded its rating to Outperform which previously was Peer Perform but kept the price unchanged to $160.
On March 18, 2025, Evercore ISI started tracking the stock assigning a In-line rating and target price of $155.Evercore ISI initiated its In-line rating on March 18, 2025, with a $155 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 15 ’25 when Hunt Anthony sold 26,447 shares for $123.71 per share. The transaction valued at 3,271,688 led to the insider holds 109,854 shares of the business.
Hunt Anthony bought 26,447 shares of RGEN for $3,394,208 on May 15 ’25. On Mar 17 ’25, another insider, Hunt Anthony, who serves as the Director of the company, sold 26,756 shares for $152.51 each. As a result, the insider received 4,080,663 and left with 136,301 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 6449820160 and an Enterprise Value of 6974522880. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.92 while its Price-to-Book (P/B) ratio in mrq is 3.25. Its current Enterprise Value per Revenue stands at 10.723 whereas that against EBITDA is 61.508.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.06, which has changed by -0.10287082 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is -7.95%, while the 200-Day Moving Average is calculated to be -18.13%.
Shares Statistics:
RGEN traded an average of 759.36K shares per day over the past three months and 686650 shares per day over the past ten days. A total of 56.18M shares are outstanding, with a floating share count of 53.12M. Insiders hold about 5.46% of the company’s shares, while institutions hold 102.30% stake in the company. Shares short for RGEN as of 1749772800 were 3391049 with a Short Ratio of 4.96, compared to 1747267200 on 3398902. Therefore, it implies a Short% of Shares Outstanding of 3391049 and a Short% of Float of 8.140001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
